Drugs / Lixivaptan
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00675701 | May → Sep 2008 | — | CardioKine Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03487913 | Sep 2018 → Dec 2019 | autosomal dominant polycystic kidney disease | Palladio Biosciences | Completed | No outcome recorded |
| Phase 2 | NCT01055912 | Jan → Sep 2010 | congestive heart failure | CardioKine Inc. | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT05208866 | Feb → Jun 2022 | autosomal dominant polycystic kidney disease | Palladio Biosciences | Terminated | No outcome recorded |
| Phase 3 | NCT04064346 | Oct 2021 → Aug 2022 | autosomal dominant polycystic kidney disease | Palladio Biosciences | Terminated | No outcome recorded |
| Phase 3 | NCT04152837 | Sep 2020 → Jul 2022 | autosomal dominant polycystic kidney disease | Palladio Biosciences | Terminated | No outcome recorded |
| Phase 3 | NCT00876876 | Jul 2009 → Aug 2010 | — | CardioKine Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT00876798 | Jun 2009 → Nov 2010 | — | CardioKine Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00660959 | Apr 2008 → Jun 2010 | — | CardioKine Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00578695 | Jan 2007 → Jun 2010 | — | CardioKine Inc. | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03717181 | — | polycystic kidney disease | Palladio Biosciences | No longer available | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2010-11-03 | Biogen | Biogen Idec and Cardiokine Dissolve Collaboration for Lixivaptan biogen.com ↗ |
| 2008-02-14 | Biogen | Biogen Idec and Cardiokine Initiate Phase III Clinical Trial for Lixivaptan in Congestive Heart Failure Patients with Hyponatremia biogen.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lixivaptan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00876798 ↗ |
| Known as | CRTX 080 | ChEMBL registry synonym — accepted as the source's own label CHEMBL49429 ↗ |
| Known as | Lixar | ChEMBL registry synonym — accepted as the source's own label CHEMBL49429 ↗ |
| Known as | VPA 985 | ChEMBL registry synonym — accepted as the source's own label CHEMBL49429 ↗ |
| Known as | WAY-VPA-985 | ChEMBL registry synonym — accepted as the source's own label CHEMBL49429 ↗ |
| Action | Inhibit | “Lixivaptan is a potent, non-peptide selective antagonist of the vasopressin V2 receptor.” NCT01055912 ↗1“Vasopressin V2 receptor antagonist” CHEMBL49429 ↗ |
| Modality | Small molecule | — CHEMBL49429 ↗ |
| Route | Oral | “Oral Capsule” NCT00578695 ↗ |
| Target | AVPR2 | “Vasopressin V2 receptor antagonist” CHEMBL49429 ↗ |